Abstract:Buprenorphine, an FDA-approved drug for opioid addiction, is increasingly being used during pregnancy for maintenance therapy in place of methadone. Very limited data exist defining the metabolic pathways of sublingual buprenorphine during pregnancy. Characterization of buprenorphine metabolism in pregnant women is useful in refining dosage regimens and evaluating potential contributors to neonatal abstinence syndrome (NAS). The objective of this study was to evaluate the concentration of buprenorphine metabolites (N-demethylated and glucuronidated) following sublingual administration during pregnancy and postpartum. We recruited 12 women with singleton gestation, between 7 0/7-31 6/7 weeks gestation, who were receiving buprenorphine twice daily for opioid addiction. These women were studied at least once during pregnancy and once after delivery. PK1a studies were performed between 14-26 weeks, PK1b studies were performed between 27-40 weeks of gestation and PK2 was performed 4-18 weeks postpartum. On the day of study, blood was withdrawn prior to the daily morning dose of buprenorphine and at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8 and 12 hours post-dose. Plasma was separated and analyzed by LCMS-MS to calculate PK parameters. To assess metabolic activity we compared the concentration of each buprenorphine metabolite to the parent drug, quantified by the area under the plasma concentration-time curve (AUC). Table 1 compares mean (± SD) of the ratio of the metabolites’ AUC to the parent drug’s AUC during PK1a, PK1b, and PK2 using log2 transformed mixed models. Buprenorphine glucuronide was significantly greater in the latter part of pregnancy than postpartum. There appeared to be little change in the formation of norbuprenorphine. Norbuprenorphine glucuronide was not measurable in all subjects for all time points and is not included in this analysis. The increased activity of the glucuronidation enzymes during pregnancy may be responsible for the lower drug concentrations seen in pregnant compared to postpartum women on sublingual buprenorphine. Since all the metabolic products of buprenorphine are believed to have biological activity, they should be measured when relating maternal dose or plasma concentrations to outcomes such as NAS or maternal satiety while the mother is on buprenorphine maintenance therapy.

Differential Effects of Prenatal Buprenorphine and Methadone on Postnatal Growth and Gene Expression in the Nucleus Accumbens

Molecular and Long-Term Behavioral Consequences of Neonatal Opioid Exposure and Withdrawal in Mice.

The effects of buprenorphine and morphine during pregnancy: Impact of exposure length on maternal brain, behavior, and offspring neurodevelopment

Gestational buprenorphine exposure: Effects on pregnancy, development, neonatal opioid withdrawal syndrome, and behavior in a translational rodent model

Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: A population-based study

Effects of prenatal exposure to methadone or buprenorphine and maternal separation on anxiety-like behavior in rats

Decreased myelin-related gene expression in the nucleus accumbens during spontaneous neonatal opioid withdrawal in the absence of long-term behavioral effects in adult outbred CFW mice

Maternal exposure to buprenorphine, but not methadone, during pregnancy reduces social play behavior across two generations of offspring

Prenatal methadone exposure and child developmental outcomes in 2-year-old children

Prenatal buprenorphine exposure decreases neurogenesis in rats

Buprenorphine and methadone differentially alter early brain development in human cortical organoids

Assessing Neonatal Opioid Withdrawal Syndrome Severity as a Function of Maternal Buprenorphine Dose and Umbilical Cord Tissue Concentrations

In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome

481 Interactions between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome

DNA methylation patterns in umbilical cord blood from infants of methadone maintained opioid dependent mothers

Differences in withdrawal symptoms, microglia activity, and cognitive functioning in rats exposed to continuous low-dose heroin in-utero

Maternal Methamphetamine Exposure Influences Behavioral Sensitization and Nucleus Accumbens DNA Methylation in Subsequent Generation

Methadone Interrupts Neural Growth and Function in Human Cortical Organoids.

Maternal care behavior and physiology moderate offspring outcomes following gestational exposure to opioids

281: Pregnancy Alters the Metabolism of Sublingual Buprenorphine